drugset / Trial / NCT06433362

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

NCT06433362

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single arm, multicenter study to evaluate the safety and efficacy of CMOEP in patients with untreated peripheral T-cell lymphoma.

Timeline

Start
2024-06-01
Primary completion
2025-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 750 mg/m2
Subject Etoposide Small molecule 60 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 18 mg/m2
Subject Prednisone Other / unclassified
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous
Subject Vindesine Small molecule 3 mg/m2